| NAME | : | Ivosidenib |
| BOBOT | : | 582.97 |
| RUMUS | : | C28H22ClF3N6O3 |
| THERAPEUTIC INDC | : | Ivosidenib is approved for use in the treatment of relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test ... |
| CATEGORIES | : | Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / OAT3 Inhibitors / P-glycoprotein/ABCB1 Inhibitors / P-glycoprotein/ABCB1 Substrates / QTc Prolonging Agents |
| STRUCTURE | : |  |